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Background: The aim of the study was to evaluate the simplicity, safety, patients’ preference, 
and convenience of the administration of insulin using the pen device versus the conventional 
vial/syringe in patients with diabetes.  
Methods: This observational study was conducted in multiple community pharmacies in Lebanon. 
The investigators interviewed patients with diabetes using an insulin pen or conventional vial/
syringe. A total of 74 questionnaires were filled over a period of 6 months. Answers were entered 
into the Statistical Package for Social Sciences (SPSS) software and Excel spreadsheet. t-test, 
logistic regression analysis, and correlation analysis were used in order to analyze the results.
Results: A higher percentage of patients from the insulin pen users group (95.2%) found the 
method easy to use as compared to only 46.7% of the insulin conventional users group (P 0.001, 
relative risk [RR]: 2.041, 95% confidence interval [CI]: 1.178–3.535). Moreover, 61.9% and 
26.7% of pen users and conventional users, respectively, could read the scale easily (P 0.037, 
RR 2.321, 95% CI: 0.940–5.731), while 85.7% of pen users found it more convenient shifting to 
pen and 86.7% of the conventional users would want to shift to pen if it had the same cost. Pain 
perception was statistically different between the groups. A much higher percentage (76.2%) 
of pen users showed no pain during injection compared to only 26.7% of conventional users 
(P 0.003, RR 2.857, 95% CI: 1.194–6.838).
Conclusion: The insulin pen was significantly much easier to use and less painful than the 
conventional vial/syringe. Proper education on the methods of administration/storage and 
disposal of needles/syringes is needed in both groups.
Keywords: diabetes, insulin pen, conventional vial/syringe, hypoglycemia, secretagogue, pain 
perception, needle phobia
Introduction
Diabetes mellitus is an epidemic critical disease requiring continuous medical care. 
The World Health Organization (WHO) estimated that diabetes mellitus is projected 
to become the seventh leading cause of death within the coming 15 years.1  Due to 
population growth alone, the number of patients suffering from diabetes worldwide 
is expected to double from 171 million in 2000 to more than 366 million in 2030. The 
estimated cost of treatment is also expected to increase to US$192 billion in 2020.2 Type 
1 diabetes mellitus results from the total destruction of the pancreatic beta cells leading 
to total insulin deficiency, thus rendering the body wholly dependent on exogenous 
insulin for therapy. Type 2 diabetes mellitus often requires multiple oral antidiabetic 
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or hypoglycemic agents and/or insulin as an option in step 2 
therapy.3 The American Heart Association (ADA) consensus 
algorithm lists insulin as an option after life style modification 
and metformin or when HbA
1c
8.5%.4
Studies have shown that insulin therapy can improve 
insulin sensitivity and glycemic control as well as decrease 
the incidence of micro- and macrovascular complications 
such as neuropathy, retinopathy, nephropathy, and cardio-
vascular diseases.4 The ADA recommends for all patients 
with diabetes, who are not at high risk for hypoglycemia, a 
tight glycemic control, which is defined as the target level of 
HbA
1c
 7%. This association stated that a total cost savings 
of $50 billion could be achieved over 10 years in all patients 
with diabetes if this target level is attained.5 Diabetes teams 
need to work along with their patients to ensure that insulin 
therapy is initiated early enough, when needed, to maintain 
tight glycemic control and minimize diabetes-related diseases 
and costs. Despite this known benefit of insulin therapy, 
physicians and patients are still reluctant to start this therapy 
for multiple reasons. In fact, the UKPDS (United Kingdom 
Prospective Diabetes Study) showed that 27% of patients with 
type 2 diabetes mellitus refused initiating insulin when asked 
by their doctors, and, in the DAWN (Diabetes  Attitudes, 
Wishes and Needs) study, 50%–55% of physicians delayed 
insulin therapy for their patients because of the fear of non-
compliance and poor patient adherence.6,7
The National Health and Nutrition Examination Survey 
(NHANES) proved that the use of insulin dropped drastically 
from 24% to 16% between 1990 and 2000.8 This reduction can 
be explained by several factors, one of which is associated with 
the complexity of the administration of insulin using the vial/
syringe device at that time.9 Other reasons may be the distress 
associated with the fear of self-injection, social stigma, and 
troublesome dosing – especially when patients have to mix dif-
ferent types of insulin, as well as the fear of hypoglycemia.2 All 
these factors make patients hesitant to initiate this “complex 
therapy”.8 With the development of insulin pens, the patients’ 
perceptions of insulin therapy improved and patients were able 
to overcome some of the barriers stated earlier.9
Insulin pens were first introduced in 1985 by Novo 
Nordisk (NovoPen®), but the latter still needed the load-
ing step, which was totally eliminated in 1989 by the 
development of the first fully disposable prefilled insulin pen 
(NovoLet®).10,11 The aim behind such a development was to 
improve treatment compliance. Pens are simple to use, and 
patient preference and satisfaction with insulin pens may lead 
to better adherence and thus better glycemic control which, 
in return, leads to reduced health costs.12
Pawaskar et al compared the costs related to starting an 
insulin pen versus the conventional vial/syringe in patients 
with type 2 diabetes mellitus. One thousand three hundred 
and thirty-two patients were analyzed and the total annual 
health care costs averaged $14,900 in the pen group versus 
$32,000 in the syringe group. Interestingly enough is the fact 
that the cost of hospitalization of the pen group was more 
reduced.13 This finding was emphasized by Asamoah in his 
article titled “Insulin pen-the ‘iPod’ for insulin delivery (why 
pen wins over syringe)”.14 An explanation of such cost saving 
is the possibility of less insulin wastage due to expiration 
with the insulin pen since one vial contains 1,000 units of 
insulin as compared of one box of 5 pens containing 1,500 
units of insulin in total.3 Another study, by Lee et al analyzed 
patients’ adherence and hypoglycemic incidents in patients 
who converted to pen use. It showed that converting to pen 
significantly improved medication adherence and reduced 
hypoglycemic episodes (odds ratio [OR]: 0.50, P0.05).15
Moreover, the simplicity of pen use is particularly impor-
tant not only to older patients suffering from impaired manual 
dexterity and tremors, but also for younger individuals who 
are too busy to devote much time to their injections.16,17 
Insulin pens are portable, thus they offer greater flexibility in 
day-to-day living especially in younger patients. Lee et al 
in another study looked at the quality-of-life improvement 
when shifting to insulin pens in 65 patients. Patients received 
an assessment of glucose control after 12 weeks and were 
asked to fill out a questionnaire on health-related quality 
of life. The study showed that the physical component of 
the Short-Form Health Survey (SF-36) was significantly 
higher in the pen group with a P-value of 0.037.18 It, thus, 
revealed that using insulin pens improved glycemic control 
and health-related quality of life in patients with diabetes, 
hence improving functional status, which is an important 
aspect of this millennium. 
The objective of this study was to assess the simplicity, 
safety, patients’ preference, and convenience of the 
administration of insulin using the pen versus the conven-
tional vial/syringe device. Other endpoints target the aware-
ness of the method of administration of insulin via the pen 
device and the conventional vial/syringe. In addition, some 
endpoints will be stratified by possible confounders.
Methods
setting and design
A concurrent, prospective observational study was conducted 
at five community pharmacies in Lebanon, in the Beirut 
area, over a period of 6 months. Patients with diabetes using 
Patient Preference and Adherence 2015:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
519
insulin pens versus vial/syringe devices in patients with diabetes
insulin and visiting pharmacies to purchase insulin products 
were asked if they were willing to participate in the study. 
Patients whose family members came to the pharmacies 
to buy the insulin were asked about the telephone number 
of the patients and about the possibility of calling them. 
Phone interviews were done when patients consented to 
participate in the study. The investigators had prepared a 
structured questionnaire that was used in order to conduct the 
survey (Figures S1 and S2). The study was approved by the 
Lebanese American University Institutional Review Board 
and a waiver of consent was obtained to fill out the 
questionnaire.  
inclusion/exclusion criteria
Patients with type 1 and type 2 diabetes mellitus, aged 
10 years or older from both genders, and using insulin by 
self-injection or receiving help from family members for 
insulin administration were included. Female patients taking 
insulin for gestational diabetes, hospitalized patients, patients 
on insulin pumps, patients having severe systemic diseases 
such as active cancer, and patients with psychiatric disorders 
were excluded. Patients receiving insulin injections from 
health care professionals were excluded as well.
sources of data
The primary, secondary, and tertiary investigators inter-
viewed patients entering community pharmacies from 9 am 
until 4 pm. The study consisted of a well-structured ques-
tionnaire used for data collection that is divided into two 
segments. The first segment targeted conventional insulin 
users, whereas the second targeted insulin pen users. Each 
segment is divided into three sections. The first two sections 
were common to both segments. The first section consisted 
of 13 general questions about the patient’s demographics 
as well as diabetes type, duration of insulin use, physician 
visit frequency, fasting blood glucose and HbA
1c
 monitoring, 
concomitant oral hypoglycemic use, and other comorbidities. 
The second section included 12 questions highlighting the 
administration techniques. The last section targeted either 
insulin pen users or conventional vial/syringe users. At the 
end of data collection, 74 surveys had been filled out. The 
questions were converted to endpoints in order to meet 
the objective of the study. The primary endpoints were the 
simplicity and safety of administration, as well as patients’ 
preference and convenience. Simplicity of administration 
was analyzed according to answers in the survey about the 
following: how easy it is to use the device (pen versus con-
ventional) and to read the scale, and how comfortable the 
responder would feel using a pen without a guide. Safety 
of administration was targeted by questions related to pain 
perception, hypoglycemic episodes, and bruises at the site of 
administration. Information about patients’ preference and 
convenience were collected through patients’ responses to 
two different questions: patients on insulin pens were asked if 
it was more convenient when shifting to pen, and those using 
a conventional vial/syringe were asked if they would prefer 
shifting to a pen if it were the same cost as a conventional 
vial/syringe. A secondary endpoint was the awareness of the 
method of administration in terms of A: proper storage (in 
the fridge before opening and at room temperature or fridge 
after opening); B: method of shaking (rubbing as a proper 
method); C: angle of administration (answered as 45° or 90° 
as a correct method according to the level of obesity [body 
mass index]); D: rotating the site of injection (rotating within 
the same region for morning dose and another region for 
evening dose or rotating between sites from one injection to 
another); E: cleaning the site of administration; F: examining 
the suspension before use; G: using a new needle for every 
injection; H: throwing away needles directly after injection; 
and I: releasing trapped air from the vial/syringe (for con-
ventional device) or hearing the click (for pen). 
“Administration procedures” included questions about 
the awareness of each method (items A–I) mentioned in 
the previous paragraph. The responses were converted to 
either “incorrect” (0) or “correct” (1). “Safety and simplic-
ity” included information about pain perception, bruises, 
hypoglycemia, ease of use, and reading the scale. Again, 
answers were converted to either “0” as more negative impact 
or “1” as less negative impact on patients. Correlation was 
conducted to analyze the relationship between ease of use 
and insulin duration. Three categories were developed for 
ease of use: 1) easy; 2) intermediate; and 3) hard, and two 
categories were used for insulin duration: 1) 1–5 years and 
2) 5 years. As for the relation between reading the scale 
and age, a correlation was also performed. The patients were 
divided into two groups: 0) all ages (60 years); and 1) ages 
60 years. Three categories were developed for reading 
the scale: 1) easy; 2) intermediate; and 3) hard. Bruises at 
the site of administration were also stratified by the type of 
other comorbidities and the likelihood of taking concomitant 
anticoagulant or antiplatelet drugs that increase the risk of 
bleeding. A correlation was conducted to analyze the relation-
ship between patients having bruises with patients having 
stroke/ischemic heart disease, and with patients who do not 
correctly rotate between the sites of injection. Hypoglyce-
mic episodes were classified as less frequent (less than one 
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episode in 6 months) or more frequent (more than one episode 
in 6 months). Hypoglycemia episodes were identified if the 
patient experienced symptoms of hypoglycemia that may or 
may not be confirmed by glucose level check and were strati-
fied by the age and whether or not the patient took other oral 
hypoglycemic agents. A correlation was conducted to relate 
the frequency of hypoglycemia ([0] less frequent; [1] more 
frequent) to two possible confounders such as secretagogue 
use ([0] not using secretagogues; [1] using secretagogues) 
and age group, mainly elderly ([0] all ages 60 years; [1] 
ages 60 years).
statistical analysis
Data were processed and analyzed through the application of 
two software programs: the Statistical Package for the Social 
Sciences (SPSS version 19; IBM Corporation, Armonk, NY, 
USA) and Microsoft Excel. Responses were tabulated and 
cross-tabulated. Percentages, P-values, RR, and 95% con-
fidence interval (CI) were calculated. Data were converted 
to dichotomous, binary-type variables. Thus, t-test, logistic 
regression, and binary correlation were applied in order to 
analyze the results.  
Results
In this study, a total of 74 patients were surveyed, of 
whom 43 were using an insulin pen and 31 were using a 
conventional vial/syringe. Demographic information is 
shown in Table 1.
Most of the patients using the insulin pen (81%) had been 
taught about the administration techniques by health care 
professionals (physicians or pharmacists). Of patients using 
insulin for more than 5 years, 52.38% of pen users found their 
device easy to use versus 33.33% of the conventional vial/
syringe users. For pen users (Table 2), there was a significant 
negative correlation between ease of use and the duration of 
insulin use at 5% level of significance.
When asked about how comfortable they would feel using 
a pen without a guide, 62% of insulin pen users answered 
“quite comfortable” and “very comfortable”. As for reading 
the scale, 61.9% of pen users could read the scale easily ver-
sus 26.7% of conventional users (P 0.037, RR 2.321, 95% 
CI: 0.940–5.731). Because the elderly are prone to dexterity 
issues, this outcome (reading the scale) was stratified by age 
group, mainly for patients who were above 60 years of age 
having the most difficulty with reading the scale. Among 
pen users, 71.19% of the patients found reading the scale 
hard or intermediate, versus 76.45% of conventional users. 
Table 1 Baseline demographic percentages of the 74 patients
Demographics Insulin pen Conventional 
insulin device
Sex
Female 29.7% 21.6%
Male 28.4% 20.3%
Age (years)
10–20 0.0% 0.0%
21–30 5.4% 0.0%
31–40 2.7% 2.7%
41–60 23.0% 13.5%
60 27.0% 25.7%
BMI
normal 14.9% 9.5%
Overweight 23.0% 24.3%
Obese 20.3% 8.1%
Diabetes type
Type 1 4.1% 2.7%
Type 2 54.1% 39.2%
Diabetes duration (years)
1–5 6.8% 5.4%
6–10 12.2% 0.0%
11–20 20.3% 14.9%
20 18.9% 21.6%
Insulin use duration (years)
1–5 20.3% 5.4%
6–10 35.1% 24.3%
11–20 2.7% 9.5%
20 0.0% 2.7%
Insulin units per day
10–20 21.6% 5.4%
21–30 9.5% 9.5%
31–40 10.8% 8.1%
41–50 8.1% 13.5%
50 8.1% 5.4%
Other oral hypoglycemic
secretagogues 12.2% 16.2%
Other antidiabetic 45.9% 25.7%
Insulin injection frequency/day
Once 21.6% 10.8%
Twice 17.6% 20.3%
Other 18.9% 10.8%
HbA1c monitoring frequency
every 3 months 10.8% 10.8%
every 6 months 32.4% 16.2%
6 months 12.2% 14.9%
nA 2.7% 0.0%
Comorbidities
Others 40.5% 23.0%
stroke/ihD 17.6% 18.9%
Abbreviations: BMi, body mass index; ihD, ischemic heart disease; nA, not available.
There was a significant positive correlation between age 
and reading the scale at 5% level for all patients and pen 
patients only (Table 2). Pain perception is a major barrier to 
accepting insulin therapy. A statistically significant higher 
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percentage (76.2%) of pen users reported no pain during 
injection compared to only 26.7% of the conventional users 
(P 0.003, RR 2.857, 95% CI: 1.194–6.838).
No statistically significant difference was seen between 
the groups in the incidence of hypoglycemia (P 0.681, RR 
1.33, 95% CI: 0.666–1.854). In both insulin user groups, only 
28.79% of those who reported more frequent episodes of 
hypoglycemia used secretagogues concurrently. The results 
in Table 2 show no significant correlation between hypo-
glycemia and secretagogue use. However, for all patients, 
there was a significant positive correlation between age and 
hypoglycemia at 5% level.
An additional safety outcome addressed in our study was 
the percentage of bruises at the site of administration. More 
patients among the conventional users developed bruises at 
the site of administration (73.3%) as compared to 47.6% of 
the pen users. However, this difference was not statistically 
significant (P 0.123, RR 1.964, 95% CI: 0.773–4.994). When 
stratified by concomitant stroke or arrhythmias as a disease 
state, it was found that 75.11% of the patients in both groups 
who developed bruises had concurrent stroke or arrhythmias, 
though there was no significant relationship between bruises 
and stroke/ischemic heart disease or rotation of injection 
sites from 74 tested samples for all patients, pen users, and 
conventional users (Table 2).
Moving to another primary endpoint, which studied 
patients’ preference and convenience, 85.7% of pen users 
found it more convenient when shifting to pen, and 86.7% of 
conventional users would want to shift to the pen if it were 
the same cost as the conventional vial/syringe.
safety and simplicity impact analysis
Safety and simplicity criteria were classified as a separate 
category including the following five safety–simplicity (SS) 
factors: pain perception; bruises; hypoglycemia; ease of use; 
and reading the scale.
correlation analysis
A binary correlation between SS factors was conducted to 
analyze their impact on patients using the following scale: 
(0) more painful, more bruises, more hypoglycemia, hard to 
use, hard to read the scale and (1) less painful, less bruises, 
less hypoglycemia, easy to use, easy to read the scale, for 
both types of patients (conventional users; pen users). Pen 
use was significantly positively correlated to pain and ease 
of use at 1% level, reading the scale at 5% level, and bruises 
at 10% level (Table 3). However, there was no correlation 
with hypoglycemia episodes.
regression analysis
A logistic regression analysis was conducted to analyze the 
impact of choosing the pen method over the conventional 
method due to SS factors. Results are shown in Table 3. Pain 
perception and ease of use were the two significant factors. 
The factor of bruises, however, needs a larger sample size to 
investigate, which has a margin of possibility of 12%. Since 
Table 2 correlations
Type All patients Pen users Conventional users
Relationship between ease of use and duration of insulin use
correlation -0.18 -0.53 -0.02
P-value 0.292 0.042 0.921
Relationship between age and reading the scale
correlation 0.37 0.44 0.20
P-value 0.028 0.044 0.473
Relationship between hypoglycemia and secretagogues
correlation 0.08 0.17 0.39
P-value 0.647 0.457 0.152
Relationship between hypoglycemia and age
correlation 0.36 0.34 0.39
P-value 0.029 0.135 0.152
Relationship between bruises and stroke/IHD
correlation 0.17 0.13 0.18
P-value 0.333 0.560 0.510
Relationship between bruises and site rotation
correlation 0.12 0.14 0.04
P-value 0.477 0.552 0.887
Abbreviation: ihD, ischemic heart disease.
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Table 3 safety–simplicity (ss) factors
Binary correlation between pen and conventional methods and SS factors
SS factors Pain perception Bruises Hypoglycemia Ease of use Reading the scale
correlation 54% 30% 0% 55% 35%
P-value 0.001 0.073 1 0 0.038 
Logistic regression analysis for SS factors; G (-2 log likelihood): 21.510
SS factors Pain perception Bruises Hypoglycemia Ease of use Reading the scale Constant
Coefficient 3.98 2.14 -2.20 5.32 0.97 -5.67
standard error 1.58 1.39 1.73 2.23 1.42 2.27
P-value 0.01 0.12 0.20 0.20 0.49 0.01 
Logistic regression analysis for SS factors; G (-2 log likelihood): 23.553
SS factors Pain perception Bruises Ease of use Constant
Coefficient 3.33 1.53 4.32 -5.40
standard error 1.26 1.10 1.62 1.94
P-value 0.008 0.164 0.008 0.005 
Note: g: most used indicator in logistic regression to quantify the likelihood.
pain perception, ease of use and bruises are rather significant 
impact factors for treatment, a logistic regression analysis 
was conducted for the three mentioned factors (Table 3) and 
Equation (1) was developed: 
gˆ(x)=  -5.40 + 3.33 × Pain Perception  
+ 1.53 × bruises + 4.32 × Ease of Use (1)
Equation (1) could be used to identify the type of patient 
according to the categories of answers to pain perception, 
bruises, and ease-of-use questions. For example, for patient 
ID #1 with a pain perception answer equal to 1 (meaning the 
device is painful), bruises answer equal to 0 (meaning the 
patient is not developing bruises at the site of administration), 
and ease-of-use answer equal to 1 (meaning the device is easy 
to use), gˆ(x) = -5.40 + 3.33 × 1 +1.53 × 0 + 4.32 × 1 = 2.25, 
y = π (x) = egˆ(x)/1 + egˆ(x) = e2.25/1 + e2.25 = 0.90, which means 
there is a 90% chance that the patient will be a pen user, and 
the actual patient (ID #1) is a pen user.
A secondary endpoint included patients’ awareness of the 
method of administration of insulin. Only 50% of all insulin 
users (conventional and pen users) showed correct rotation 
of the injection site. Moreover, 63.9% of all insulin users 
were storing insulin correctly. As for the angle of adminis-
tration, 44.4% of all insulin users showed a correct angle of 
administration. Similarly, 52.7% of all insulin users showed a 
correct method of shaking. When assessing the proper aseptic 
techniques of administration/disposal or cleaning the site of 
administration, unfortunately only 30.5% of all insulin users 
cleaned the site of injection before administration and only 
27.7% used a new needle for every injection. Moreover, few 
patients (16.6%) examined the suspension/solution before 
Table 4 Administration procedures
Percentage of correct administration procedures: comparison between insulin pen and conventional users
Administration proceduresa A B C D E F G H I
Pen 38% 52% 52% 48% 24% 0% 19% 24% 86%
conventional 100% 53% 33% 53% 40% 40% 40% 53% 40%
P-value 0 0.96 0.27 0.74 0.31 0 0.18 0.07 0
Factor analysis of the administration procedures for insulin pen and conventional users
Administration proceduresa A B C D E F G H I
correlation -0.64 -0.01 0.19 -0.06 -0.17 -0.53 -0.23 -0.30 0.48
P-value 0 0.957 0.27 0.744 0.31 0.0001 0.176 0.072 0.0003 
Logistic regression analysis of administration procedures
Administration proceduresa A  B C D E F G H Constant
Coefficient -38.42 -0.53 19.04 -0.53 0.53 -38.48 -15.03 -22.46 38.95
standard error 12.33 1.53 8.45 1.53 1.53 15.33 47.31 45.84 12.33
P-value 1 0.73 1 0.73 0.73 1 1 1 1
Notes: aA: storage. B: method of shaking. c: angle of administration. D: rotating the site of injection. e: cleaning the site of administration. F: examining the suspension before 
use. g: using a new needle for every injection. h: throwing away needle directly after injection. i: releasing trapped air from vial/syringe (for conventional device) or hearing 
the click (for pen).
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injections; 40% of the conventional users released trapped 
air before injections; and 36.1% of all insulin users threw 
needles away directly after injection.
Administration procedures analysis
t-test analysis
The percentages of correctness for all administration procedures 
are calculated in Table 4, and a t-test was conducted to test the 
significance level of difference on administration procedures 
between pen and conventional users. Pen users, as compared 
to conventional users, had a significant lower percentage of 
correctness on storage (38% versus 100%), on examining the 
suspension/solution (0% versus 40%), and on throwing the 
needle away directly after injection (24% versus 53%). 
correlation analysis
A binary correlation was conducted between patient types 
([0] conventional; [1] pen) and administration procedures 
([0] incorrect; [1] correct). Results are shown in Table 4. 
Seven out of nine administration procedures were negatively 
correlated. Administration procedures A, F, and I were 
significantly correlated at 1% level, and procedure H was 
significantly correlated at 10% level.  
regression analysis
A logistic regression was conducted to test how the 
administration factors influence patients’ preference of 
insulin pen over conventional vial/syringe device (Table 4). 
The results show that no administration procedure was a 
significant factor at 5% level.
Discussion
Diabetes mellitus is a chronic disease that has a huge impact 
on patients’ lives. Patients with diabetes need special attention 
and care in order to manage their lives. On top of frequent glu-
cose monitoring, frequent physician visits, daily monitoring 
of carbohydrate intake, and lifestyle modifications, patients 
who are to be initiated on insulin therapy face several social 
and economic burdens that make this therapy more bother-
some. From this perspective comes the attention on patients’ 
preference for the type of insulin therapy.10 Our study targeted 
several outcomes to compare between insulin pen users and 
conventional vial/syringe users, and showed that patients 
have a higher preference for insulin pens in terms of ease of 
use. The results parallel those of Korytkowski et al in which 
74% of patients indicated a preference for the pen over the 
vial/syringe (95% CI: 71%–87%), compared with 20% who 
preferred the vial/syringe; 74% considered the pen easier to 
use overall, compared with 21% for the vial/syringe; and 85% 
of insulin pen users found reading the scale easy to use com-
pared to only 10% of the conventional vials users who believe 
that reading the scale is easy to read.9 Insulin vials/syringes are 
disposable, light-weight, transparent (such that insulin can be 
inspected), and come with different needle sizes and syringes, 
thus are suitable for high doses up to 100 units.19 However, 
they are less socially acceptable, necessitate carrying a bottle 
and syringe, and require refrigeration for storage and adequate 
visual acuity when drawing a dose. Insulin pens, on the other 
hand, are more socially acceptable, portable, have a larger 
scale which simplifies dosages, and offer an audible “click” 
with each unit that overcomes many visual problems.20 In our 
study, 86% reported hearing the click with each insulin pen 
use. Insulin pens are perceived as less painful when compared 
to a conventional vial/syringe. In fact, needle phobia has been 
studied in many clinical trials. A study about the needle gauge 
and its association with pain was studied in 30 healthy volun-
teers; 40.3% reported that a needle of 27 gauge/0.4 mm outer 
diameter was significantly more likely to cause pain compared 
with a needle of 30 gauge/0.3 mm outer diameter.9 Another 
open-label, crossover study comparing patient preference 
and pain perception between the Micro Fine Plus® 31-gauge 
and the Microtapered NanoPass® 33-gauge needles showed 
that the 33-gauge lubricant-coated needle had a significantly 
superior (P0.001) overall patient satisfaction score with less 
fear and less bleeding tendency.20
In our study, the insulin pen was significantly less 
painful and easier to use, and the scale was easier to read, 
compared to the conventional vial/syringe. Needle phobia 
may be decreased by the shorter needles (6–10 mm) found 
in the pen device compared with the conventional syringe 
(12 mm). The drawback of insulin pen use is the fact that 
they are expensive. 
The complexity of the administration of conventional 
insulin may expose the patients to serious safety implications. 
Previous studies showed that there is approximately 19% 
error in the accuracy of the insulin dose drawn and the risk of 
error is higher with conventional syringes, especially when 
drawing doses below five insulin units.21,22 The results of our 
study showed that both groups (29.63% and 41.26% of pen 
users and conventional users, respectively) were developing 
hypoglycemic episodes more frequently, which might be 
correlated to inaccuracy in insulin dosing. However, a major 
limitation of this study is that it did not quantify the number 
of hypoglycemic episodes nor the severity of hypoglycemia. 
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Another major limitation is that the study is not a controlled 
one and the investigators did not have information about the 
exact dose of insulin taken nor knowledge about the lifestyle, 
food intake, or visual acuity status of the patients. 
Other limitations include the small sample size, the lim-
ited number of community pharmacies included in the study, 
and the short duration of the study; added to this, the length 
of the questionnaire used made some patients reluctant 
to agree to be interviewed due to their limited free time. 
Moreover, most of the patients who entered the pharmacies 
had their insulin injected by the pharmacy staff, which led 
to their exclusion. 
The results of this study dictate a need for insulin 
techniques awareness for the Lebanese population. The 
majority of our patients did not clean the site of injection 
before injecting insulin, did not rotate the site of adminis-
tration, did not use a new needle for every injection, and 
did not throw away the needle directly after injections. 
However, those are the key factors for proper insulin 
administration in order to avoid infections. Patients should 
be instructed on the correct injection depth, injection sites, 
and injection technique. Insulin depth should be sufficient 
to avoid intramuscular injections that lead to rapid absorp-
tion and higher risk of hypoglycemia.23 For future refer-
ence, whenever needed, proper injection counseling for 
all insulin-naïve patients should provide an indispensable 
step in diabetes management and aid in reaching effective 
and safe diabetes control with the least possible injection 
complications.24,25
Conclusion
In this study, more patients preferred the insulin pen over the 
conventional insulin device. The insulin pen was reported by 
patients to be easier to use and less painful. Hypoglycemic 
episodes and bruises at the site of administration were greater 
in patients using conventional insulin as compared to insulin 
pen users; however, a large sample size is needed and other 
factors should be investigated in order to have a significant 
relation. Patients in both groups need more awareness about 
the method of administration, aseptic injection techniques, and 
proper disposal of needles/syringes. Further research is desired 
to determine whether there is a difference between the insulin 
pen devices in terms of efficacy and acceptability. In fact, 
pharmacists can contribute to the safe use of insulin by offering 
patient counseling in the community setting prior to dispensing 
insulin. This might minimize errors related to administration, 
storage, and proper disposal of needles/syringes. 
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